Kåre Schultz

2020

In 2020, Kåre Schultz earned a total compensation of $15.7M as President and Chief Executive Officer at Teva Pharmaceutical Industries, a 36% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$3,055,920
Salary$2,000,000
Stock Awards$9,999,970
Other$668,628
Total$15,724,518

Schultz received $10M in stock awards, accounting for 64% of the total pay in 2020.

Schultz also received $3.1M in non-equity incentive plan, $2M in salary and $668.6K in other compensation.

Rankings

In 2020, Kåre Schultz's compensation ranked 368th out of 13,090 executives tracked by ExecPay. In other words, Schultz earned more than 97.2% of executives.

ClassificationRankingPercentile
All
368
out of 13,090
97th
Division
Manufacturing
125
out of 5,620
98th
Major group
Chemicals And Allied Products
43
out of 2,253
98th
Industry group
Drugs
38
out of 1,953
98th
Industry
Pharmaceutical Preparations
26
out of 1,458
98th
Source: SEC filing on April 21, 2021.

Schultz's colleagues

We found four more compensation records of executives who worked with Kåre Schultz at Teva Pharmaceutical Industries in 2020.

2020

Hafrun Fridriksdottir

Teva Pharmaceutical Industries

Executive Vice President, Global Research and Development

2020

Brendan O'Grady

Teva Pharmaceutical Industries

Executive Vice President, North America Commercial

2020

Eric Drap

Teva Pharmaceutical Industries

Executive Vice President, Global Operations

2020

Eli Kalif

Teva Pharmaceutical Industries

Chief Financial Officer

News

You may also like